Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 4 de 4
Filtrar
Mais filtros

Métodos Terapêuticos e Terapias MTCI
Base de dados
Tipo de documento
País de afiliação
Intervalo de ano de publicação
1.
AAPS PharmSciTech ; 21(5): 184, 2020 Jul 06.
Artigo em Inglês | MEDLINE | ID: mdl-32632735

RESUMO

Fibromyalgia (FM) is a chronic disease that has as main characteristic generalized musculoskeletal pain, which can cause physical and emotional problems to patients. However, pharmacological therapies show side effects that hamper the adhesion to treatment. Given this, (-)-linalool (LIN), a monoterpene with several therapeutic properties already reported in scientific literature as anti-depressive, antinociceptive, anti-inflammatory, and antihyperalgesic also demonstrated therapeutic potential in the treatment of FM. Nevertheless, physicochemical limitations as high volatilization and poor water-solubility make its use difficult. In this perspective, this present research had performed the incorporation of LIN into polymeric nanocapsules (LIN-NC). Size, morphology, encapsulation efficiency, cytotoxicity, and drug release were performed. The antihyperalgesic effect of LIN-NC was evaluated by a chronic non-inflammatory muscle pain model. The results demonstrated that the polymeric nanocapsules showed particle size of 199.1 ± 0.7 nm with a PDI measurement of 0.13 ± 0.01. The drug content and encapsulation efficiency were 13.78 ± 0.05 mg/mL and 80.98 ± 0.003%, respectively. The formulation did not show cytotoxicity on J774 macrophages. The oral treatment with LIN-NC and free-LIN increased the mechanical withdrawal threshold on all days of treatment in comparison with the control group. In conclusion, LIN-NC is a promising proposal in the development of phytotherapy-based nanoformulations for future clinical applications.


Assuntos
Monoterpenos Acíclicos/administração & dosagem , Anti-Inflamatórios/administração & dosagem , Fibromialgia/tratamento farmacológico , Nanocápsulas , Polímeros/administração & dosagem , Monoterpenos Acíclicos/farmacocinética , Monoterpenos Acíclicos/uso terapêutico , Animais , Anti-Inflamatórios/farmacocinética , Liberação Controlada de Fármacos , Humanos , Tamanho da Partícula , Solubilidade
2.
Food Chem Toxicol ; 135: 110940, 2020 Jan.
Artigo em Inglês | MEDLINE | ID: mdl-31693914

RESUMO

Eplingiella fruticosa (Lamiaceae), formally known as Hyptis fruticosa, is an important aromatic medicinal herb used in folk medicine in northeastern Brazil. We aimed to evaluate the anti-hyperalgesic effect of essential oil obtained from E. fruticosa (HypEO) complexed with ßCD (HypEO-ßCD) in a chronic widespread non-inflammatory muscle pain animal model (a mice fibromyalgia-like model, FM). The HypEO was extracted by hydro distillation and its chemical composition was determined by GC-MS/FID. Moreover, Fos protein expression in the spinal cord was assessed by immunofluorescence. (E)-caryophyllene, bicyclogermacrene, 1,8-cineole, α-pinene, ß-pinene and 21 other compounds were identified in the HypEO. The treatment with HypEO-ßCD produced a longer-lasting anti-hyperalgesic effect compared to HypEO, without alterations in motor coordination or myorelaxant effects. Moreover, HypEO and HypEO-ßCD produced a significant anti-hyperalgesic effect over 7 consecutive treatment days. Immunofluorescence assay demonstrated a decrease in Fos protein expression in the spinal cord (p < 0.001). We demonstrated that the anti-hyperalgesic effect produced by HypEO was improved after complexation with ß-CD and this seems to be related to the central pain-inhibitory pathway, suggesting the possible use of E. fruticosa for chronic pain management.


Assuntos
Analgésicos/uso terapêutico , Hiperalgesia/tratamento farmacológico , Lamiaceae/química , Mialgia/tratamento farmacológico , Óleos Voláteis/uso terapêutico , beta-Ciclodextrinas/uso terapêutico , Analgésicos/isolamento & purificação , Animais , Masculino , Camundongos , Óleos Voláteis/isolamento & purificação , Folhas de Planta/química , Proteínas Proto-Oncogênicas c-fos/metabolismo , Medula Espinal/efeitos dos fármacos , Medula Espinal/metabolismo
3.
Neurochem Int ; 131: 104530, 2019 12.
Artigo em Inglês | MEDLINE | ID: mdl-31425746

RESUMO

Chronic pain is a continuous or recurring pain which exceeds the normal course of recovery to an injury or disease. According to the origin of the chronic pain, it can be classified as inflammatory or neuropathic. This study aimed to evaluate the antinociceptive and anti-inflammatory effect of (-)-α-bisabolol (BIS) alone and complexed with ß-cyclodextrin (ßCD) in preclinical models of chronic pain. Chronic pain was induced by Freund's Complete Adjuvant (FCA) or partial lesion of the sciatic nerve (PLSN). Swiss mice were treated with BIS, BIS-ßCD (50 mg/kg, p.o) or vehicle (control) and mechanical hyperalgesia, thermal hyperalgesia, muscle strength and motor coordination were evaluated. In addition, levels of TNF-α and IL-10 and expression of the ionized calcium-binding adapter protein (IBA-1) were assessed in the spinal cord of the mice. The complexation efficiency of BIS in ßCD was evaluated by High-Performance Liquid Chromatography. BIS and BIS-ßCD reduced (p < 0.001) mechanical and thermal hyperalgesia. No alterations were found in force and motor coordination. In addition, BIS and BIS-ßCD inhibited (p < 0.05) TNF-α production in the spinal cord and stimulated (p < 0.05) the release of IL-10 in the spinal cord in PLSN-mice. Further, BIS and BIS-ßCD reduced IBA-1 immunostaining. Therefore, BIS and BIS-ßCD attenuated hyperalgesia, deregulated cytokine release and inhibited IBA-1 expression in the spinal cord in the PLSN model. Moreover, our results show that the complexation of BIS in ßCD reduced the therapeutic dose of BIS. We conclude that BIS is a promising molecule for the treatment of chronic pain.


Assuntos
Citocinas/metabolismo , Gliose/tratamento farmacológico , Hiperalgesia/induzido quimicamente , Inflamação/tratamento farmacológico , Sesquiterpenos Monocíclicos/uso terapêutico , Neuralgia/tratamento farmacológico , beta-Ciclodextrinas/uso terapêutico , Animais , Proteínas de Ligação ao Cálcio/biossíntese , Adjuvante de Freund , Temperatura Alta , Hiperalgesia/metabolismo , Inflamação/metabolismo , Masculino , Camundongos , Proteínas dos Microfilamentos/biossíntese , Força Muscular/efeitos dos fármacos , Neuralgia/induzido quimicamente , Neuralgia/metabolismo , Desempenho Psicomotor/efeitos dos fármacos , Neuropatia Ciática/tratamento farmacológico , Medula Espinal/metabolismo , Estereoisomerismo
4.
Cytokine ; 96: 152-160, 2017 08.
Artigo em Inglês | MEDLINE | ID: mdl-28414969

RESUMO

OBJECTIVE: Rotavirus is a leading cause of childhood diarrhoea. Rotavirus vaccines are effective against severe rotavirus gastroenteritis, but have lower efficacy in low income countries in Africa. Anti-rotavirus treatment is not available. This study reviews the literature of animal studies evaluating whether cytokine mediated pathways of immune activation could improve rotavirus therapy. METHODS: We performed a systematic review of articles in English published from 2010 to 2016 reporting agents with in vivo antirotavirus activity for the management of rotavirus infection. The search was carried in PubMed, EMBASE, Scopus and Web of Science. Animal experiments where cytokines were investigated to assess the outcome of rotavirus therapy were included. RESULTS: A total of 869 publications were identified. Of these, 19 pertained the objectives of the review, and 11 articles described the effect of probiotics/commensals on rotavirus infection and immune responses in animals. Eight further in vivo studies evaluated the immunomodulating effects of herbs, secondary metabolites and food-derived products on cytokine responses of rotavirus-infected animals. Studies extensively reported the regulatory roles for T-helper (Th)1 (interferon gamma (IFN-γ), interleukin (IL)-2, IL-12) and Th2 (IL-4, IL-6, IL-10) cytokines responses to rotavirus pathogenesis and immunity, inhibiting rotavirus infection through suppression of inflammation by viral inhibition. CONCLUSION: Th1 and Th2 cytokines stimulate the immune system, inhibiting rotavirus binding and/or replication in animal models. Th1/Th2 cytokine responses have optimal immunomodulating effects to reduce rotavirus diarrhoea and enhance immune responses in experimental rotavirus infection.


Assuntos
Citocinas/metabolismo , Infecções por Rotavirus/imunologia , Infecções por Rotavirus/terapia , Rotavirus/imunologia , Animais , Diarreia/tratamento farmacológico , Diarreia/virologia , Modelos Animais de Doenças , Gastroenterite/tratamento farmacológico , Gastroenterite/virologia , Humanos , Imunomodulação , Inflamação/tratamento farmacológico , Camundongos , Fitoterapia , Probióticos/uso terapêutico , Rotavirus/isolamento & purificação , Infecções por Rotavirus/prevenção & controle , Metabolismo Secundário , Células Th1/imunologia , Células Th2/imunologia
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA